other material
confidence high
sentiment neutral
materiality 0.45
Atossa to issue stapled CVRs giving holders 25% of first priority review voucher proceeds, capped at $50M
ATOSSA THERAPEUTICS, INC.
- Board approved one CVR per ATOS share; holders would receive 25% of net proceeds from monetization of Atossa's first qualifying rare pediatric disease priority review voucher, capped at $50M.
- CVRs would transfer attached to ATOS shares, would not trade separately or have their own CUSIP, and would expire if no qualifying voucher is awarded by December 31, 2036 unless the Board extends.
- Atossa holds two FDA rare pediatric disease designations for (Z)-endoxifen, in Duchenne muscular dystrophy and McCune-Albright syndrome; no product approved, no voucher awarded to date.
- Record date for the distribution has not yet been set by the Board of Directors. Atossa cited prior disclosed priority review voucher sales of $100M-$220M over the preceding 18-24 months.